康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1681)

POSITIVE PROFIT ALERT

This announcement is made by Consun Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the six-month period ended 30 June 2015, it is expected that the Group would record an increase of approximately 25% to 30% in profit attributable to equity shareholders of the Company for the six-month period ended 30 June 2015 as compared with that for the six-month period ended 30 June 2014, which was mainly attributable to the continued growth in sales of the Group's kidney medicines and medical contrast medium during the period, and the continuous improvement in business operation and management efficiency and cost control measurements during the period.

The information set out in this announcement is only based on the information currently available to the Company and the Board's preliminary assessment of the unaudited consolidated management accounts of the Group for the six-month period ended 30 June 2015, subject to finalization and other potential adjustments (if necessary), and is not based on any figures or information audited or reviewed by the Company's auditor. Shareholders and potential investors are advised to read carefully the interim results announcement of the Group for the six-month period ended 30 June 2015, which is expected to be published in late August 2015.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 24 July 2015

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong as non-executive Director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.